Safety assessment of drug metabolites: Characterization of chemically stable metabolites

被引:47
作者
Humphreys, W. Griffith [1 ]
Unger, Steve E. [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Pharmaceut Candidate Optimizat, Princeton, NJ 08543 USA
关键词
D O I
10.1021/tx6002547
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug molecules are typically subjected to a variety of biotransformation reactions, and the metabolites formed through these reactions must be considered when conducting safety testing programs for new chemical entities. Metabolites that are chemically stable sometimes have pharmacological activity profiles similar to those of the parent compound but rarely have potent activity against off-target receptors that is unique relative to the parent profile. This fact argues for the thorough testing of drug metabolites for their pharmacological activity. It also argues for a significantly lower need for the thorough characterization and quantitation of stable metabolites not thought to substantially contribute to the pharmacodynamic effect. Given the tremendous resource requirements involved in the thorough characterization of drug metabolites, a more flexible, tiered approach to stable metabolite characterization would seem to provide the best utilization of resources while still allowing a complete evaluation of the toxicological profile of a new drug.
引用
收藏
页码:1564 / 1569
页数:6
相关论文
共 33 条
[1]   Reactive intermediates and the pathogenesis of adverse drug reactions: The toxicology perspective [J].
Amacher, DE .
CURRENT DRUG METABOLISM, 2006, 7 (03) :219-229
[2]   Drug metabolites in safety testing [J].
Baillie, TA ;
Cayen, MN ;
Fouda, H ;
Gerson, RJ ;
Green, JD ;
Grossman, SJ ;
Klunk, LJ ;
LeBlanc, B ;
Perkins, DG ;
Shipley, LA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) :188-196
[3]   Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology [J].
Baillie, Thomas A. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (07) :889-893
[4]   CHARACTERISTICS OF CHEMICAL-BINDING TO ALPHA-2U-GLOBULIN INVITRO - EVALUATING STRUCTURE-ACTIVITY-RELATIONSHIPS [J].
BORGHOFF, SJ ;
MILLER, AB ;
BOWEN, JP ;
SWENBERG, JA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 107 (02) :228-238
[5]   Toxin-induced models of Parkinson's disease [J].
Bové J. ;
Prou D. ;
Perier C. ;
Przedborski S. .
NeuroRX, 2005, 2 (3) :484-494
[6]   MODE OF INSERTION OF MICONAZOLE, KETOCONAZOLE AND DEACYLATED KETOCONAZOLE IN LIPID LAYERS - A CONFORMATIONAL-ANALYSIS [J].
BRASSEUR, R ;
VANDENBOSCH, C ;
VANDENBOSSCHE, H ;
RUYSSCHAERT, JM .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (14) :2175-2180
[7]   Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate [J].
Funk, C ;
Pantze, M ;
Jehle, L ;
Ponelle, C ;
Scheuermann, G ;
Lazendic, M ;
Gasser, R .
TOXICOLOGY, 2001, 167 (01) :83-98
[8]   Cytochrome P450s and other enzymes in drug metabolism and toxicity [J].
Guengerich, FP .
AAPS JOURNAL, 2006, 8 (01) :E101-E111
[9]   Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes [J].
Gum, RJ ;
Hickman, D ;
Fagerland, JA ;
Heindel, MA ;
Gagne, GD ;
Schmidt, JM ;
Michaelides, MR ;
Davidsen, SK ;
Ulrich, RG .
BIOCHEMICAL PHARMACOLOGY, 2001, 62 (12) :1661-1673
[10]   Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway [J].
Kalgutkar, AS ;
Taylor, TJ ;
Venkatakrishnan, K ;
Isin, EM .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :243-249